On November 4, 2026 Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, reported that initial data from a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease, will be presented in a poster session at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition, which is taking place December 12-15, 2026 in New Orleans, LA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 2 ALPS trial was initiated by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and led by V. Koneti Rao, MD, FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic) at NIH Clinical Center. There currently is no cure or approved treatment for ALPS and the disorder is managed by a variety of empirical methods aimed at addressing pathological changes caused by the disease, such low blood-cell counts (cytopenias), excessive lymphocyte production (lymphoproliferation), enlarged spleen or lymph nodes, and lymphoma. Treatments may include corticosteroids such as prednisone and other immunosuppressive medications to modulate the immune system, or cancer therapies to address lymphoma.
As of August 3, 2026, three ALPS patients were enrolled in the Phase 2 trial and completed one year of treatment with a 200 mg twice per day dose of soquelitinib. The treatment was well tolerated, with no grade 3 or 4 adverse events and no interruptions in therapy. All three patients were able to discontinue background medications including steroids and reported improvement in ALPS related systemic symptoms. Corvus believes the data supports continued enrollment in the trial and based on the results to-date, we plan to explore longer treatment durations and enroll younger pediatric patients.
Details regarding the poster presentation are as follows:
Session Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III
Session Date: December 14, 2026
Session & Presentation Time: 6:00 – 8:00 PM
Publication Number: 4743
Title: Clinical assessment of soquelitinib, an interleukin-2-inducible T cell kinase (ITK) inhibitor, for treatment of autoimmune lymphoproliferative syndrome (ALPS)-FAS
The abstract accepted for presentation can be viewed online at the ASH (Free ASH Whitepaper) abstracts site here, and will appear in the November supplemental issue of Blood.
(Press release, Corvus Pharmaceuticals, NOV 4, 2026, View Source [SID1234674205])